Latest News

Mutant-Allele Tumor Heterogeneity (MATH) in head, neck squamous cell carcinoma patients is effective marker, along with HPV status, of improved patient outcome

Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient?s HPV status provides an effective indicator of improved patient outcome, according to research.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Motivation explains disconnect between testing, real-life functioning for seniors

  • Novel technologies advance brain surgery to benefit patients

  • Mutated gene linked to both autism, intellectual disability

  • New concerns over top-selling blood thinning drug after investigation

  • Immune response may cause harm in brain injuries, disorders

  • New mechanism for neurodegeneration found

  • New tools help neuroscientists analyze 'big data'

  • Six new genetic risk factors for Parkinson's found

  • CEOs who motivate with 'fightin' words' shoot themselves in the foot

  • Knowledgeable consumers more likely to buy when given fewer options

  •